Clinical nephrology最新文献_第5页

Fibrillary glomerulonephritis in a patient with rheumatoid arthritis: A case report and review of the literature. 类风湿性关节炎患者的纤维性肾小球肾炎：病例报告和文献综述。

IF 1.1 4区医学

Clinical nephrology Pub Date : 2024-10-01 DOI: 10.5414/CN111259

Olivia Schreiber, Michael Chau, Solomon Dawson, Vinay Srinivasan

引用次数: 0

Risk factors for in-hospital mortality among patients hospitalized with COVID-19 and end-stage kidney disease. COVID-19 和终末期肾病住院患者院内死亡的风险因素。

IF 1.1 4区医学

Clinical nephrology Pub Date : 2024-10-01 DOI: 10.5414/CN111323

Jackson Heilbronn, Amir Abdipour, Giv Heidari-Bateni, Mohammad Sharif, Sahib Grewal, Sergio Infante, Kwame Agyeman, Zohreh Gholizadeh Ghozloujeh, Lida Gharibvand, Sayna Norouzi

{"title":"Risk factors for in-hospital mortality among patients hospitalized with COVID-19 and end-stage kidney disease.","authors":"Jackson Heilbronn, Amir Abdipour, Giv Heidari-Bateni, Mohammad Sharif, Sahib Grewal, Sergio Infante, Kwame Agyeman, Zohreh Gholizadeh Ghozloujeh, Lida Gharibvand, Sayna Norouzi","doi":"10.5414/CN111323","DOIUrl":"10.5414/CN111323","url":null,"abstract":"Aims: The mortality rate for -COVID-19 infection varies significantly depending on age and comorbidities but remains high in hospitalized patients overall. Several retrospective studies have identified patients with end-stage kidney disease (ESKD) to be at increased risk. The objective of this study was to study in-hospital outcomes of ESKD patients at an academic medical center and identify characteristics that place them at a higher risk for in-hospital mortality.Materials and methods: A retrospective chart review was conducted including adult patients (≥ 18 years old) admitted to Loma Linda Medical Center for COVID-19 infection with a previous diagnosis of ESKD. Patients with prior kidney transplants were excluded. The main outcome of this study was the rate of in-hospital mortality.Results: 21 of the 91 patients died with a mortality rate of 23%. Age, D-dimer > 0.4 µg/mL, ejection fraction less than 50%, and ferritin > 300 ng/mL were predictors for mortality in unadjusted univariate analysis. Adjusted multivariable analysis demonstrated that only an ejection fraction of less than 50% was associated with increased mortality risk.Conclusion: Cardiovascular disease is the leading cause of mortality for ESKD patients and also places them at increased risk of mortality in the setting of severe COVID-19 infection.","PeriodicalId":10396,"journal":{"name":"Clinical nephrology","volume":" ","pages":"187-191"},"PeriodicalIF":1.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis. 环硅酸锆钠和聚苯乙烯磺酸钙对中重度高钾血症患者快速降钾的有效性和安全性分析。

IF 1.1 4区医学

Clinical nephrology Pub Date : 2024-10-01 DOI: 10.5414/CN111226

XiaoJuan Fu, Sen Zhang, Fang Gao, Nan Mao

{"title":"Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis.","authors":"XiaoJuan Fu, Sen Zhang, Fang Gao, Nan Mao","doi":"10.5414/CN111226","DOIUrl":"10.5414/CN111226","url":null,"abstract":"Background: Hyperkalemia is a common complication of chronic kidney disease (CKD). This study aims to investigate the efficacy and safety of sodium zirconium cyclosilicate and calcium polystyrene sulfonate in reducing potassium in patients with acute and severe hyperkalemia in CKD who are not undergoing dialysis.Materials and methods: A retrospective real-world study was conducted among 73 patients with non-dialysis chronic kidney disease who were hospitalized in the First Affiliated Hospital of Chengdu Medical College from June 2020 to June 2022. 33 patients treated with sodium zirconium cyclosilicate were categorized as SZC group, and the other 40 patients treated with calcium polystyrene sulfonate were categorized as CPS group. Serum potassium, serum sodium, magnesium, calcium, and phosphorus levels were examined. Adverse reactions were recorded during medication.Results: Significantly decreased serum potassium was observed in both groups, whereas the potassium reduction was higher in the SZC group than in the CPS group at 2, 4, 24, and 48 hours after medication while there was no statistically significant difference in the serum potassium level between the two groups at 72 hours. For those people whose initial potassium exceeded 6 mmol/L, the potassium reduction was more obvious in the SZC group than in the CPS group at 2 and 4 hours after medication. The control rate of hyperkalemia in the SZC group was significantly higher than in the CPS group at 4, 24, and 48 hours. No distinct change was observed in serum sodium, calcium, magnesium, and phosphorus before and 72 hours after medication. No severe adverse reactions occurred.Conclusion: Sodium zirconium cyclosilicate has a more obvious effect on reducing potassium particularly for those patients with moderate to severe hyperkalemia who need rapid potassium reduction.","PeriodicalId":10396,"journal":{"name":"Clinical nephrology","volume":" ","pages":"223-231"},"PeriodicalIF":1.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kidney complications of Wilson disease and its treatments: A case report and literature review. 威尔逊病的肾脏并发症及其治疗方法：病例报告和文献综述。

IF 1.1 4区医学

Clinical nephrology Pub Date : 2024-10-01 DOI: 10.5414/CN111402

Maria Salman, Ayub Akbari, Gregory L Hundemer

引用次数: 0

Efficacy of urokinase in maintaining patency of hemodialysis catheters: A meta-analysis. 尿激酶保持血液透析导管通畅的功效：荟萃分析。

IF 1.1 4区医学

Clinical nephrology Pub Date : 2024-10-01 DOI: 10.5414/CN111239

Jiaxiu Deng, Weixiang Luo, Weiwei Zhang, Shiyi Xiong, Liping Wang

{"title":"Efficacy of urokinase in maintaining patency of hemodialysis catheters: A meta-analysis.","authors":"Jiaxiu Deng, Weixiang Luo, Weiwei Zhang, Shiyi Xiong, Liping Wang","doi":"10.5414/CN111239","DOIUrl":"10.5414/CN111239","url":null,"abstract":"Background: Catheter malfunctions are associated with reduced blood flow and interrupted dialysis during hemodialysis.Aim: This meta-analysis aimed to determine whether the use of urokinase to lock hemodialysis catheters can maintain their patency and prevent catheter-related bloodstream infections (CRBSIs).Materials and methods: The PubMed, Cochrane Library, Web of Science, Embase, and Chinese medical databases were searched for controlled trials of hemodialysis catheter locking using urokinase from database inception until July 15, 2021. The primary outcome was catheter malfunction, and the secondary outcomes were the peak catheter blood flow rate (Qb) and CRBSIs.Results: Across 16 trials, 1,041 patients were randomized to receive either urokinase/urokinase mixture (treated) or heparin (control) locks once or thrice a week. Locking with urokinase alone or in combination with another substance significantly prevented catheter malfunction. The effect on Qb was significant, with that in the treated group being better than in the control group. Similarly, the incidence of CRBSIs in the treated group was lower.Conclusion: Urokinase locking maintains catheter patency more effectively than heparin. Prophylactic locking with urokinase or urokinase mixtures reduces incidences of catheter malfunction, which ensures the smooth progression of hemodialysis and reduces patient medical costs. The results of this study have important clinical implications and will provide guidance to medical practitioners globally.","PeriodicalId":10396,"journal":{"name":"Clinical nephrology","volume":" ","pages":"212-222"},"PeriodicalIF":1.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Denosumab for immobilization-induced hypercalcemia in patients with end-stage renal disease. 地诺单抗治疗终末期肾病患者因固定诱发的高钙血症。

IF 1.1 4区医学

Clinical nephrology Pub Date : 2024-10-01 DOI: 10.5414/CN111361

Jugal Thaker, Abdallah S Geara

引用次数: 0

Hypercalcemia of malignancy: Cancer treatment can be a cause as well. 恶性肿瘤引起的高钙血症：癌症治疗也可能是原因之一。

IF 1.1 4区医学

Clinical nephrology Pub Date : 2024-09-01 DOI: 10.5414/CN111403

Hassan Izzedine, Rose Mary Attieh, Farhana Begum, Yee-Ming Melody Cheung, Kenar D Jhaveri

引用次数: 0

Clinical management of unremitting nephrogenic diabetes insipidus. 顽固性肾源性糖尿病的临床治疗。